In short
Chronic fatigue syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is characterised by profound, persistent fatigue that does not improve with rest, accompanied by post-exertional malaise (PEM), cognitive impairment, unrefreshing sleep, and often autonomic and immune symptoms. At CLCC, care for chronic fatigue syndrome follows a five-step structured assessment: Assess, Identify, Reduce, Restore, Continue, addressing the systemic contributors alongside standard medical treatment, rather than symptom management alone.
About This Condition
Chronic fatigue syndrome is a multi-system condition, not medically unexplained, but medically under-investigated.
Chronic fatigue syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is characterised by profound, persistent fatigue that does not improve with rest, accompanied by post-exertional malaise (PEM), cognitive impairment, unrefreshing sleep, and often autonomic and immune symptoms. The defining feature that distinguishes CFS from general fatigue is PEM: a worsening of all symptoms following physical or cognitive exertion that may be delayed 12–24 hours and last days to weeks.
CFS is frequently described as medically unexplained, because standard investigation returns largely normal results. This reflects the inadequacy of standard investigation, not the absence of pathology. Consistent findings in CFS research include: mitochondrial dysfunction in immune and muscle cells, gut microbiome disruption, elevated gut permeability, neuroinflammation detectable on specialist imaging, HPA axis dysregulation, and specific nutritional deficiencies. CLCC addresses these measurable contributors systematically.
Symptoms
Common symptoms and presentations.
Profound fatigue lasting more than 6 months, not relieved by rest
Post-exertional malaise: worsening of all symptoms after physical or cognitive exertion
Unrefreshing sleep, waking as exhausted as when going to bed
Cognitive impairment, 'brain fog', poor concentration, word-finding difficulty
Orthostatic intolerance, worsening symptoms when standing, improved when lying down
Widespread pain, muscle aching, joint pain, headaches
Immune symptoms, sore throat, tender lymph nodes, low-grade temperature
Light and sound sensitivity
Gut symptoms, IBS pattern is very common in CFS
Symptom fluctuation, periods of relative stability followed by significant crashes
Contributing Factors
What drives and sustains this condition.
Mitochondrial dysfunction
Impaired ATP production in immune and muscle cells is among the most well documented findings in CFS research. This directly produces the profound energy deficit and explains the post-exertional crash, cells cannot regenerate energy at the rate that activity demands.
Gut microbiome disruption
CFS patients show altered gut microbiome composition compared to controls, with reduced diversity and elevated inflammatory bacterial species. The gut-brain axis disruption contributes to both neurological symptoms and immune dysregulation.
Neuro-immune dysregulation
Neuroinflammation and aberrant immune activation are documented in CFS, producing the immune symptoms (sore throat, tender nodes) and contributing to cognitive impairment through direct neurological inflammation.
HPA axis dysregulation
Cortisol patterns in CFS are characteristically blunted, the opposite of the elevated cortisol seen in burnout. This hypocortisolism produces poor stress response capacity, worsening fatigue, and impaired immune regulation.
The CLCC Method: All Five Steps
Assessment first. Then all five steps, applied specifically.
Comprehensive mitochondrial, gut, nutritional, and neuro-immune assessment
CoQ10, ALC, B12, iron, ferritin, vitamin D assessed. Gut microbiome indicators and barrier integrity evaluated. HPA axis cortisol pattern assessed. Autonomic function and orthostatic indicators reviewed. Baseline severity scored using validated CFS instruments.
Identify dominant contributors, mitochondrial, gut, neuro-immune, or HPA axis
CFS presentations vary considerably. Post-viral CFS (most common following infections) may have stronger neuro-immune involvement. Gut-prominent CFS shows strong digestive co-symptoms. Identifying the dominant pattern determines the care plan structure and progression.
Graduated mitochondrial support alongside gut and nutritional correction
CoQ10 and ALC at therapeutic doses for mitochondrial support. B12, iron, and vitamin D correction. Gut restoration. Anti-inflammatory dietary protocol. Crucially: paced activity, not rest alone, not aggressive exercise, staged to avoid post-exertional relapse.
Track energy envelope, PEM frequency, and functional capacity at monthly intervals
Validated CFS outcome measures reviewed monthly. Energy envelope documented, the sustainable activity level without triggering PEM. Nutritional markers rechecked at 3 months. Progression to increased activity only when energy envelope expands without PEM.
Long-term staged recovery with sustained systemic support
CFS recovery is slow and non-linear. The Continue phase provides structured long-term support, monitoring mitochondrial markers, gut health, and activity tolerance, preventing relapses through pacing guidance and adjusting nutritional support as recovery progresses.
FAQs
Common questions about care.
Is graded exercise therapy (GET) appropriate for CFS?+
Standard graded exercise therapy, progressively increasing exercise load, is not appropriate for CFS and is associated with worsening in a significant proportion of patients due to post-exertional malaise. CLCC uses paced activity, activity within the patient's current energy envelope, expanded only as mitochondrial function and energy capacity genuinely improve. This is fundamentally different from GET.
What is the relationship between CFS and long COVID?+
Long COVID post-viral fatigue shares significant clinical and biological overlap with ME/CFS, including post-exertional malaise, cognitive impairment, and mitochondrial dysfunction. The CLCC approach to CFS applies directly to post-COVID fatigue presentations, addressing the same underlying contributors.